Upcoming Federal Policy Shifts Will Open New Opportunities In Cannabis Markets

Key Takeaways

• Expansion in Europe and category diversification are driving strong growth, margin improvements, and long-term revenue potential as global cannabis markets develop.
  
• Operational efficiencies and a solid financial position support continued cost optimization, strategic acquisitions, and international market entry for ongoing earnings growth.
  
• Persistent regulatory hurdles, market pressures, and industry headwinds continue to constrain Tilray's revenue growth, profitability, and exposure to solvency and dilution risks.

Catalysts

A lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally.

• Tilray's international cannabis business is achieving rapid organic growth, with European cannabis revenue up 112% YoY (excluding Australia) and significant share gains in Germany due to regulatory tailwinds, broader medical adoption, and expanding legalization-supporting a long runway for top-line revenue acceleration as global cannabis markets open.
  
• Sustained innovation and consumer focus in wellness, energy drinks, non-alcoholic beverages, and hemp-based foods positions Tilray to capture the surge in demand for plant-based, functional, and health-oriented products, which should drive diversified, higher-margin revenues and gross margin expansion.
  
• Operational scale from strategic acquisitions (craft beer/spirits) and production footprint consolidation (now 90% in-house) is enabling continued cost optimization, SKU rationalization, and manufacturing efficiency, translating into stronger gross/net margins and improved EBITDA in upcoming periods.
  
• Ongoing consolidation and stabilization in Canada's cannabis sector and a shift toward higher-margin SKUs (e.g., premium flower, beverages, edibles) are reducing price compression and illicit market share, while regulatory reforms (potential for broader retail/access, excise tax changes) offer future revenue and profitability upside.
  
• Tilray's robust balance sheet, substantial cash reserves, and ongoing debt reduction afford flexibility to pursue geographic expansion, new international market entries in Europe/Middle East/Asia, and opportunistic acquisitions-enhancing long-term earnings growth and financial resilience.

Tilray Brands Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Tilray Brands's revenue will grow by 12.0% annually over the next 3 years.
• Analysts are not forecasting that Tilray Brands will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Tilray Brands's profit margin will increase from -156.7% to the average CA Pharmaceuticals industry of 19.6% in 3 years.
• If Tilray Brands's profit margin were to converge on the industry average, you could expect earnings to reach $235.7 million (and earnings per share of $1.71) by about June 2029, up from -$1.3 billion today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 7.2x on those 2029 earnings, up from -0.4x today. This future PE is lower than the current PE for the CA Pharmaceuticals industry at 15.3x.
• Analysts expect the number of shares outstanding to grow by 5.8% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.92%, as per the Simply Wall St company report.

Risks

• Persistently slow and uncertain progress on U.S. cannabis legalization continues to limit Tilray's addressable market, with management citing that "U.S. regulatory changes have not advanced the way we'd hoped," which has suppressed share price, led to multi-billion dollar impairment charges, and risks continued stagnation in revenue and market cap.
  
• Ongoing price compression, illicit market competition, and heavy excise tax burdens in the Canadian cannabis market have significantly impacted revenues-management noted price compression cost over $250 million in five years-potentially limiting future revenue growth and constraining margins.
  
• Softness and overall decline in industry-wide craft beer demand, combined with "SKU rationalization," missed distribution resets, and adverse weather, resulted in weaker-than-expected beverage revenues; persistent headwinds or further category contraction will negatively impact Tilray's diversified revenue and gross margin.
  
• Long-term lack of operating profitability is evidenced by continued net losses (a net loss of $2.2 billion in FY 2025, with $31 million in cash losses from operations) and negative free cash flow (negative $114 million FY 2025), highlighting challenges in achieving structural cost efficiency and sustainable earnings, and heightening dilution or solvency risk.
  
• Increased regulatory risk in international core markets, such as potential restrictive legislation in Germany (e.g., limiting telemedicine or mail-order medical cannabis), can disrupt access, pricing, or demand and limit the scalability of high-margin international revenues that management is relying on for future growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $10.04 for Tilray Brands based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $24.0, and the most bearish reporting a price target of just $6.5.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.2 billion, earnings will come to $235.7 million, and it would be trading on a PE ratio of 7.2x, assuming you use a discount rate of 6.9%.
• Given the current share price of $4.94, the analyst price target of $10.04 is 50.8% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.